Reports
Sale
Global PD-1 and PD-L1 Inhibitors Market Size, Share, Forecast: By Type: PD-1 Inhibitors, PD-L1 Inhibitors; By Application: Hodgkin’s Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, Other Applications; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global PD-1 and PD-L1 Inhibitors Market Outlook
The global PD-1 and PD-L1 inhibitors market size was valued at USD 45.8 billion in 2023, driven by increasing incidence of cancer cases across the globe. The market is expected to grow at a CAGR of 17.96% during the forecast period of 2024-2032, with the values likely to attain USD 202.5 billion by 2032.
PD-1 and PD-L1 Inhibitors: Introduction
PD-1 and PD-L1 inhibitors are checkpoint inhibitors used to block the activity of PD-1 and PDL1 immune checkpoint proteins, commonly present on the surface of cells. These inhibitors play a pivotal role in offering immunotherapy to cancer patients. The interaction of these cell surface proteins is also engaged in the immune system suppression and occurs following infection to restrain the killing of bystander host cells and avoid autoimmune disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global PD-1 and PD-L1 Inhibitors Market Analysis
The growing incidence of cancer has propelled deeper research into various types of therapies that could be found useful in offering treatment alternatives to patients. There is heightened focus on immunotherapy, owing to the rising requirements of personalized medicine in patients. Consequently, the PD-1 and PD-L1 inhibitors market demand has seen significant upswing in recent years.
Over the years, PD-1 inhibiotrs like Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo) and PD-L1 inhibitors Atezolizumab (Tecentriq), Avelumab (Bavencio) and Durvalumab (Imfinzi) have been the most used inhibitors in the market. However, with a better understanding the human physiology and increased technical advancements, innovations keep emerging in the market. For instance, in March 2023, the FDA approved Incyte’s intravenous drug, Zynyz, which can be used to treat metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
In addition, new technologies have been introduced to improve the quality and efficacy of drugs further. In November 2023, a liquid biopsy company called Angle that offers circulating tumour cell diagnostic solutions launched its Portrait PD-L1 test. This test works to evaluate the protein expression of PD-L1 on CTCs. Therefore, the PD-1 and PD-L1 inhibitors market value is anticipated to grow further during the forecast period.
Global PD-1 and PD-L1 Inhibitors Market Segmentation
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
- PD-1 Inhibitors
- PD-L1 Inhibitors
Market Breakup by Application
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Other Applications
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global PD-1 and PD-L1 Inhibitors Market Overview
In the forecast period, North America is predicted to possess a significant PD-1 and PD-L1 inhibitors market share. This can be attributed to the rising technical advancements and the existence of a well-equipped healthcare infrastructure to integrate the new age advancements. The presence of prominent MedTech companies and research institutions is another major factor driving the market. Similarly, Europe with a robust healthcare ecosystem is a significant player in the market. The region also focuses on educating and training the medical staff to function well with all the rising innovation.
The Asia Pacific region, on the other hand, is projected to witness rapid PD-1 and PD-L1 inhibitors market growth. Given the increasing adoption of new technologies to improve the medical ecosystem and foster innovation, the region is continuously growing and developing for better patient care. The presence of an aging population is driving development. In addition, there is a significant influx of international investments, with several key healthcare players setting up new and high-end research labs in the region to leverage the academic talent available.
Global PD-1 and PD-L1 Inhibitors Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bristol Myers Squibb
- Merck & Co., Inc.
- Roche
- AstraZeneca
- Pfizer, Inc.
- Eli Lilly and Company
- Sanofi
- Regeneron Pharmaceuticals
- Novartis AG
- BIOCAD
- Cipla Limited
- MacroGenics, Inc.
- Innovent Biologics
- Jiangsu Hengrui Medicine Co., Ltd.
- Mirati Therapeutics
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Applications |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global PD-1 and PD-L1 Inhibitors Market Overview
3.1 Global PD-1 and PD-L1 Inhibitors Market Historical Value (2017-2024)
3.2 Global PD-1 and PD-L1 Inhibitors Market Forecast Value (2024-2032)
4 Global PD-1 and PD-L1 Inhibitors Market Landscape
4.1 Global PD-1 and PD-L1 Inhibitors Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global PD-1 and PD-L1 Inhibitors Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global PD-1 and PD-L1 Inhibitors Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global PD-1 and PD-L1 Inhibitors Market Segmentation
6.1 Global PD-1 and PD-L1 Inhibitors Market by Type
6.1.1 Market Overview
6.1.2 PD-1 Inhibitors
6.1.3 PD-L1 Inhibitors
6.2 Global PD-1 and PD-L1 Inhibitors Market by Applications
6.2.1 Market Overview
6.2.2 Hodgkin’s Lymphoma
6.2.3 Kidney Cancer
6.2.4 Melanoma
6.2.5 Non-Small Cell Lung Cancer
6.2.6 Other Applications
6.3 Global PD-1 and PD-L1 Inhibitors Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Online Pharmacies
6.4 Global PD-1 and PD-L1 Inhibitors Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America PD-1 and PD-L1 Inhibitors Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe PD-1 and PD-L1 Inhibitors Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific PD-1 and PD-L1 Inhibitors Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America PD-1 and PD-L1 Inhibitors Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa PD-1 and PD-L1 Inhibitors Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Supplier Landscape
16.1 Bristol Myers Squibb
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisition
16.1.5 Certifications
16.2 Merck & Co., Inc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisition
16.2.5 Certifications
16.3 Roche
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisition
16.3.5 Certifications
16.4 AstraZeneca
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisition
16.4.5 Certifications
16.5 Pfizer, Inc.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisition
16.5.5 Certifications
16.6 Eli Lilly and Company
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisition
16.6.5 Certifications
16.7 Sanofi
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisition
16.7.5 Certifications
16.8 Regeneron Pharmaceuticals
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisition
16.8.5 Certifications
16.9 Novartis AG
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisition
16.9.5 Certifications
16.10 BIOCAD
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisition
16.10.5 Certifications
16.11 Cipla Limited
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisition
16.11.5 Certifications
16.12 MacroGenics, Inc.
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisition
16.12.5 Certifications
16.13 Innovent Biologics
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisition
16.13.5 Certifications
16.14 Jiangsu Hengrui Medicine Co., Ltd.
16.14.1 Financial Analysis
16.14.2 Product Portfolio
16.14.3 Demographic Reach and Achievements
16.14.4 Mergers and Acquisition
16.14.5 Certifications
16.15 Mirati Therapeutics
16.15.1 Financial Analysis
16.15.2 Product Portfolio
16.15.3 Demographic Reach and Achievements
16.15.4 Mergers and Acquisition
16.15.5 Certifications
17 Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 45.8 billion in 2023, driven by rising prevalence of cancer cases across the globe.
The market is anticipated to grow at a CAGR of 17.96% during the forecast period of 2024-2032, likely to reach a market value of USD 202.5 billion by 2032.
The market demand is driven by increased demand for efficient cancer treatment solutions along with rising geriatric population and increased investments by the governments to support the healthcare and pharmaceutical industries.
The current market trend involves the advent of new drugs to treat rare cancer types. In March 2023, the FDA approved an intravenous drug called Zynyz, developed by Incyte which can be used to treat metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
The market can be divided into PD-1 and PD-L1 inhibitors.
These inhibitors find wide applications in Hodgkin lymphoma, kidney cancer, melanoma, and non-small cell lung cancer, among others.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Bristol Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Pfizer, Inc., Eli Lilly and Company, Sanofi, Regeneron Pharmaceuticals, Novartis AG, BIOCAD, Cipla Limited, MacroGenics, Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Ltd. and Mirati Therapeutics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER